NEW PRODUCT DEVELOPMENT

For over 25 years I have been driven through my research and industry work to advance solutions for complex problems impacting health globally. Biotechnology innovation and new product development underpin some of the most impactful public health interventions in recent generations. I have been fortunate and am grateful to have contributed to some of them as part of my work developing molecular diagnostic technologies, as well as, first-in-class genetic engineering programs for health, food and environment.

EXPERTISE
  • Genetic, genome, and molecular engineering technologies for food and protein production
  • Medical diagnostics, food safety testing, and environmental threat detection
  • Genetic, genome, and molecular engineering of human and animal therapeutics, medicines, and vaccines
  • Molecular epidemiology, epidemic intelligence, environmental and public health interventions

CURRENT TECHNOLOGY DEVELOPMENT INITIATIVES
ENVIRONMENT
  • Developing technologies for health and safety testing, environmental cleanup, ocean conservation, and natural products chemistries discovery
FOOD
HEALTH

UNIQUE QUALIFICATIONS & EXPERIENCE
HEALTH TECHNOLOGY
  • Developed groundbreaking FDA cleared products at Gen-Probe including current molecular tests ensuring safety of U.S. blood supply (HIV, HCV, HBV, West Nile Virus)
  • Launched first combined Chlamydia and Gonorrhea molecular tests, eliminating need for male genital swabbing using male/female urine specimens
  • Developed and advanced numerous diagnostic, therapeutic, and vaccine health technologies with molecular, genetic, and genome engineering platforms

GLOBAL PUBLIC HEALTH & NATIONAL SECURITY
  • Pioneered HIV CD4 mobile testing interventions in Sub-Saharan Africa to ensure efficacy of HIV anti-retroviral therapies (ART) in rural low resource settings
  • Epidemic responses: COVID-19 pandemic, Zika, dengue, malaria, tuberculosis, HIV, influenza, Chlamydia, and Gonorrhea
  • Expertise in molecular epidemiology, epidemic intelligence, environmental health, infectious disease control, and biological threat detection systems
  • Advanced numerous biodefense, biosecurity, and medical countermeasure technologies: diagnostics and detection systems, vaccines, therapeutics
  • Infectious disease testing and vector control interventions for mosquito-borne diseases (Gen-Probe, St. Gabriel’s Hospital - Malawi, Intrexon, Oxitec)

FOOD TECHNOLOGY

  • Advanced food biotechnology for first-in-class synthetic biology enabled food products and agricultural innovations at Intrexon
  • Deep expertise with gene-edited, genetically engineered, and cloned organisms serving as first-in-class for US FDA and USDA regulators

ENVIRONMENTAL INTERVENTIONS & CONSERVATION

  • Developed multiple environmental threat detection systems for biosecurity (Gen-Probe, Nanogen - Vectrant)
  • Pioneered development of gene-edited environmental clean-up systems for emerging contaminants of concern (COCs) (Intrexon)

TECHNOLOGY ANALYSIS | M&A DILIGENCE | TECHNOLOGY INNOVATION
Participated in technology diligence to support acquisition or internal development and deployment of novel biotechnology platforms and first-in-class products reviewed by FDA, USDA, EPA and USFWS regulators:
  • AquaBounty genetically engineered salmon, first GE food animal approved for human consumption (partial acquisitions)
  • Oxitec genetically engineered insects to fight agricultural pests, infectious disease carrying insects, and invasive species ($160M acquisition)
  • ViaGen cloning for food animals (subsidiary of $110M Trans Ova Genetics acquisition)
  • ViaGen Pets established for cloning of companion animals and programs enabling endangered species population expansion with cloning of archival veterinary specimens to enhance population genetics (Intrexon, ViaGen) [press] black footed ferret - NYTimes.com | Przewalski's horse - CNN.com
  • Trans Ova Genetics leading provider of bovine reproductive technologies ($110M acquisition)
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight nutritious alternative protein feed using insect larvae (joint venture)
  • BioPop biological and popular culture art and biobased consumer products (acquisition)
  • GenVec human and animal viral-based vaccine platform (acquisition)
  • Intrexon molecular vaccine and non-disclosed engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering (acquisition)
  • ILH, formerly Codexis, protein production facility in Hungary (acquisition)
  • Intrexon’s UltraVector® platform for protein engineering and gene switches for control of protein production [microbes, plants, animals, humans]
Insert text
Stacks Image 430


SUMMARY LINE ADDED IN HERE